Dermatology Archives

News and Trends 23 Jun 2023

Breakthrough treatment for skin infections?

A research team led by Kelvin Yeung from the Department of Orthopaedics and Traumatology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has designed…

June 23, 2023 - 3 minutesmins - By Jim Cornall

In Depth 3 Mar 2023

Let’s Take a Closer Look at 7 Autoimmune Diseases Biotechs are Fighting to Treat

While we mostly think of disease as being caused by bacteria or viruses, an illness can often occur when the body’s own defenses turn against itself. Here we’ll take a…

March 3, 2023 - 8 minutesmins - By Alexander Burik

News and Trends 30 Nov 2022

TrialSpark acquires immunodermatology portfolio and creates Libertas Bio

TrialSpark has announced the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences. The Libertas Bio pipeline now includes…

November 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo

Incyte has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. The deal…

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Sep 2022

Treatment for adults with chronic skin condition approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. Dupilumab is being jointly developed by Sanofi and Regeneron under…

September 29, 2022 - 4 minutesmins - By Liza Laws

News and Trends 19 Sep 2022

Kamari Pharma raises $8M in investment for development of drugs for skin diseases

An $8 million investment has been raised by Kamari Pharma following investment from the Guangzhou-Israel Biotechnology Fund (GIBF) that creates added value for Israeli, European and American companies looking to…

September 19, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Sep 2022

Regeneron and Sanofi announce published trial results in children with dermatitis

Positive results from a phase 3 trial in children aged 6 months to five years old with uncontrolled moderate-to-severe dermatitis have been published. Regeneron Pharmaceuticals, Inc. and Sanofi made the…

September 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Arcutis…

September 8, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 21 Jul 2022

Almirall launches new call to find innovative therapies for skin diseases

A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open…

July 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 19 Feb 2018

Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown?

Two clinical studies have demonstrated the capacity of Novartis' monoclonal antibody to treat both plaque and scalp psoriasis and improve patient quality of life. Not only is Novartis leading the CAR-T…

February 19, 2018 - 3 minutesmins - By Alex Dale

News and Trends 19 Feb 2018

This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline

UCB has presented positive Phase IIb results for its psoriasis drug, bimekizumab, and outlined the Phase III testing of Cimzia for the condition at the American Academy of Dermatology's annual…

February 19, 2018 - 3 minutesmins - By Alex Dale

psoriasis treatment approval morphosys 1

News and Trends 23 Nov 2017

Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe

Following its FDA approval in July, MorphoSys’ anti-IL23 antibody has been approved to treat moderate-to-severe psoriasis by the European Commission. German biotech, MorphoSys, is a leader in the field of therapeutic…

November 23, 2017 - 3 minutesmins - By Alex Dale

In Depth 17 Oct 2017

Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis

Though the psoriasis market is teeming with effective products, companies have developed ways to devise new, more effective modes of treatment. Psoriasis is a common autoimmune disorder that affects the…

October 17, 2017 - 7 minutesmins - By Diana Kwon

News and Trends 2 Oct 2017

Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe

Update (01/10/2017): The European Commission has tighter control over pricing that governments have over here Images via Tero Vesalainen, Roman Stetsyk /Shutterstock

October 2, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Morphosys Janssen Guselkumab approval psoriasis

News and Trends 18 Sep 2017

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first…

September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Jul 2017

Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links

Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that targets IL-17a. Published 22/05/2017 The EMA has taken up a…

July 20, 2017 - 3 minutesmins - By Melanie De Almeida

Interview 4 May 2017

This Belgian Startup is building the Next Generation of Diagnostic Tests

DNAlytics changes the diagnosing game. The company builds in vitro diagnosis tests that save many years for patients! I met with Thibault, the founder, to know more about the company.…

May 4, 2017 - 5 minutesmins - By External Contributor

News and Trends 30 Mar 2017

Merck Outsources the Development of its Nanobody for Psoriasis

Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase II through Phase III. As part of several partnerships between…

March 30, 2017 - 3 minutesmins - By Melanie De Almeida

Regeneron Sanofi dupilumab Atopic Dermatitis

News and Trends 29 Mar 2017

Get Ready for One of the Biggest New Drug Approvals of the Year

After Praluent, Sanofi and Regeneron have now scored their next drug approval with dupilumab, an antibody for the treatment of atopic dermatitis. With three placebo-controlled clinical trials enrolling a total of 2119 adult…

March 29, 2017 - 3 minutesmins - By Melanie De Almeida

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here's a list of the best success stories of 2016. Biotech is becoming a…

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering